Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Biopharmaceuticals

1594

Biopharmaceuticals, or Biotech drugs are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. These treatments are created through fermentation, recombinant DNA technology, and other bioprocesses.

It is common wisdom that in the current pharmaceutical market, the true action is in biologics.

In traditional pharmaceuticals, the pipeline is struggling to produce strong therapies and the growing number of drugs losing patent protection will more than offset revenues generated from new developments. For now, its fair to say the biopharmaceutical market is spared the impact of this setback as the path to generic or biosimilar development is more involved and the number of biopharmaceutical drugs facing generic competition remains limited.

Because of the nature of these therapies they will face generic threats in some areas, but not in the same magnitude as traditional therapies, thus a greater amount of information is needed to understand the market dynamics for each product. They are complex to make and thus the number of companies in the market is smaller – though competition is growing. This creates a need to keep track of research and development in the market for these therapies and for the equipment required to manufacture and process biopharmaceuticals at various stages.

RSS Feeds

All reports in Biopharmaceuticals

< prev 1  2  3  4  5  6  7  8  9  10  next >
Research Report on Chinese Bio-pharmaceutical Industry, 2012
3/21/2012 | published by: China Research and Intelligence Co., Ltd.
... bio-pharmaceutical industry. "Bio-pharmaceutical" in the report only refers to human biological products. Chinese biological product industry is an emerging industry which has only over 20 years of history. In 2011, the sales revenue of Chinese ...  |  more...
$3,000.00
Biologics Market in Brazil
3/2/2012 | published by: Frost & Sullivan
... growth hormones, and erythropoietin is provided. This service also highlights key market drivers and restraints in addition to breaking down the current and forecasted competitive scenario. The base year of the study is 2010, and ...  |  more...
$6,000.00
The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment
3/1/2012 | published by: AM Mindpower Solutions
... as market size of the pharmaceutical industry, market segmentation by Branded and Generic drugs, and Prescribed and OTC drugs and Biologics and specialty drugs segments. The report also provides information on the government regulations, export ...  |  more...
$850.00
Global Biosimilars Market Forecast to 2015
3/1/2012 | published by: RNCOS
... evolve greatly from its current state. As per the estimations of our latest report, the global biosimilars market will grow at a CAGR of around 52% during 2010-2015. With the governments and private players worldwide ...  |  more...
$1,500.00
Biosimilars: Current Situation & Future Prospects, Worldwide
3/1/2012 | published by: JustPharmaReports.com
... biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory pathway. Funds are flowing into the sector and many new partnership ...  |  more...
$3,000.00
Biologicals in Oncology Drug Pipeline Update 2012
2/21/2012 | published by: BioSeeker Group AB
... cancer. In addition, there are 17 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 676 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives ...  |  more...
$3,749.00
World Biological Drugs Market 2012-2022
2/14/2012 | published by: Visiongain
... you assess potential sales trends at world market, submarket, product and regional level to 2022. How will 20 leading biologics - including Avastin, Enbrel, Humira and Herceptin - perform from 2012? Our investigation gives you ...  |  more...
$2,642.00
Oncology Partnering Terms and Agreements
2/1/2012 | published by: Current Partnering
... analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. ...  |  more...
$2,995.00
Competitor Analysis: Anti-Obesity Peptides and Biologics
2/1/2012 | published by: La Merie Publishing
... 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. The database also contains information about discontinued projects. Credentials to ...  |  more...
$262.00
Global Biosimilars: A return to optimism?
1/23/2012 | published by: Espicom Healthcare Intelligence
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for market entry.  |  more...
$2,265.00
2011 Biotechnology Research Review
1/1/2012 | published by: BCC Research
... $8.4 billion by 2016, increasing at a compound annual growth rate (CAGR) of 18.8%. The global biobanking market was $141 billion in 2010 and is projected to expand by 30% between 2010 and 2015, increasing ...  |  more...
$850.00
Top 200 Biopharmaceuticals Industry Report (Global)
1/1/2012 | published by: Plimsoll Publishing Ltd.
... individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page per company analysis provides detailed financial analysis for each organisation, including details of; Sales ...  |  more...
$1,500.00
Analysis of European Biosimilars Market
12/20/2011 | published by: Frost & Sullivan
... participants. This study is focused on established segments in Europe including Erythropoietin, Granulocyte Colony Stimulating Factors, Human Growth Hormones and emerging segments including monoclonal antibodies, Insulin and interferon. The established market segments consist of products ...  |  more...
$6,500.00
Specialty Physicians Discuss their Opinions of the United States Biosimilars Market
12/8/2011 | published by: Frost & Sullivan
... and expectations of specialty physicians who would be expected to be among the first customers of biosimilars, with the objective of gaining insight into some of the major factors which could influence market uptake. The ...  |  more...
$10,000.00
Mobile Operators Help Enterprises Embrace Consumerization with Dual-Persona Device Solutions
11/21/2011 | published by: IDC
... to have two personas on one mobile device. The need for these solutions is being driven by the increasing prevalence of bring-your-own-device (BYOD) programs in business settings, a key outcome of the consumerization of IT.  |  more...
$1,000.00
Phytosterols and Phytostanols - Patent and Technology Report - Key players, innovators and Industry Analysis
11/17/2011 | published by: Dolcera Corporation
... Stanols are saturated sterols which are not abundant in nature and produced by the hydrogenation of sterols. Phytosterols are used in pharmaceuticals (production of therapeutic steroids), nutrition (anti-cholesterol additives in functional foods, anti-cancer properties), and ...  |  more...
$999.00
Phytosterols and Phytostanols - Patent and Technology Landscape Report - Key players, innovators and industry analysis
11/17/2011 | published by: Dolcera Corporation
... Stanols are saturated sterols which are not abundant in nature and produced by the hydrogenation of sterols. Phytosterols are used in pharmaceuticals (production of therapeutic steroids), nutrition (anti-cholesterol additives in functional foods, anti-cancer properties), and ...  |  more...
$999.00
Freedonia Focus on Biotechnology -- Pharmaceuticals
10/31/2011 | published by: Freedonia Focus
... trends, market environment, product forecasts, industry composition and leading participants. Product segments include blood modifiers, hormones and related agents, antiviral agents and other biotech pharmaceuticals. This 18 page report also includes a highlights summary and ...  |  more...
$600.00
Multi-therapy Drugs: Opportunities for Generics & Biosimilars
10/25/2011 | published by: Espicom Healthcare Intelligence
Highly-detailed analysis, outlook & forecasts of 24 leading drugs which are indicated for a range of critical conditions.  |  more...
$1,740.00
Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
10/17/2011 | published by: IMARC
... be more akin to a marathon than a sprint. IMARC Group, one of the world’s leading research and advisory firms, in its new report “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US ...  |  more...
$1,200.00
Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition
10/15/2011 | published by: Kalorama Information
... extraordinary interest in biopharmaceuticals is the ability of these large proteins to target diseases in a very specific manner, thus maximizing efficacy while minimizing side effects. Growth in the development and production of biopharmaceuticals is ...  |  more...
$3,500.00
Freedonia Focus on Biologics
9/30/2011 | published by: Freedonia Focus
... industry composition and leading participants. Product segments include monoclonal antibodies (MAbs), vaccines and toxoids, hormones, growth factors, immunomodulators, and other biologics. Market segments cover human healthcare (cancer, autoimmune disorders, infectious disease, blood disorders, diabetes and ...  |  more...
$600.00
Biologics Price Competition and Innovation (BPCI) Act - Industry Trends Creating Demand for Biosimilars
9/30/2011 | published by: GlobalData
... Creating Demand for Biosimilars”. The report is an essential source of information and analysis on the global biosimilar market opportunity. The report identifies the key trends shaping and driving the global biosimilars market. The report ...  |  more...
$500.00
Top 450 Biotechnology (Pharmaceuticals) Report (Global)
9/27/2011 | published by: Plimsoll Publishing Ltd.
... assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page per company analysis provides detailed financial analysis for each organisation, including details of; Sales growth ...  |  more...
$1,500.00
Conference Documentation: Biosimilars and Biobetters
9/27/2011 | published by: SMI Publishing, Ltd
... the progress made in last year’s meeting and further develop the ideas and strategies that were debated and discussed. Specifically, how can the pharma and generics industries best approach the rapidly emerging and developing biosimilar ...  |  more...
$800.00
< prev 1  2  3  4  5  6  7  8  9  10  next >